Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM74ZKN)

• Drug Name: HBI-3000 Drug Info
• Synonyms: Sulcardine; Multi-ion channel blocker (oral, arrhythmia), SIMM; Multi-ion channel blocker (oral/iv, arrhythmia), HUYA

Indication

Disease Entry	ICD 11	Status	REF
Heart arrhythmia	BC65	Phase 2	[1]
Atrial fibrillation	BC81.3	Phase 1	[2]

• Cross-matching ID:
  PubChem CID: 16043221
  TTD Drug ID: DM74ZKN

Molecule-Related Drug Atlas

Drug(s) Targeting Sodium channel unspecific (NaC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[4]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[5]
Zonisamide	DM0DTF7	Alcohol dependence	6C40.2	Approved	[6]
Eslicarbazepine	DMZREFQ	Seizure disorder	8A6Z	Approved	[7]
LIDOFLAZINE	DMV23GL	Angina pectoris	BA40	Approved	[8]
LOMERIZINE	DME0TC8	Migraine	8A80	Approved	[9]
Levobupivacaine	DM783CH	Anaesthesia	9A78.6	Approved	[10]
Tetrodotoxin	DMWMPRG	Bacterial infection	1A00-1C4Z	Approved	[11]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[12]
Rufinamide	DMWE60C	Epilepsy	8A60-8A68	Approved	[13]

Drug(s) Targeting Calcium channel unspecific (CaC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nicardipine	DMCDYW7	High blood pressure	BA00	Approved	[14]
Clevidipine butyrate	DMW4M97	Hypertension	BA00-BA04	Approved	[15]
Nisoldipine	DM7ISKJ	Hypertension	BA00-BA04	Approved	[16]
Felodipine	DMOSW35	Hypertension	BA00-BA04	Approved	[17]
Nimodipine	DMQ0RKZ	Cerebral vasospasm	BA85.Z	Approved	[18]
Bepridil	DM0RKS4	Chronic/stable angina	BA40.1	Approved	[19]
Isradipine	DMA5XGH	Hypertension	BA00-BA04	Approved	[19]
DIPROTEVERINE HYDROCHLORIDE	DMG8U6M	Angina pectoris	BA40	Phase 3	[20]
ATI-2042	DMWP59B	Atrial fibrillation	BC81.3	Phase 2	[21]
Nexopamil	DML5S71	Hypertension	BA00-BA04	Phase 2	[22]

Drug(s) Targeting Potassium channel unspecific (KC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nateglinide	DMLK2QH	Diabetic complication	5A2Y	Approved	[19]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[19]
Dronedarone	DMA8FS5	Angina pectoris	BA40	Approved	[2]
Dofetilide	DMPN1TW	Sinus rhythm disorder	BC9Y	Approved	[19]
Amifampridine	DMK08L3	LambertEaton myasthenic syndrome	8C62	Approved	[23]
Minoxidil	DMA2Z4F	Alopecia	ED70	Approved	[19]
Pinacidil	DMRADYL	High blood pressure	BA00	Approved	[19]
Dalfampridine	DMM0PDO	Multiple sclerosis	8A40	Approved	[24]
Ibutilide	DMKXY2R	Atrial fibrillation	BC81.3	Approved	[19]
Diazoxide	DML1538	Congenital hyperinsulinism	5A4Y	Approved	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Calcium channel unspecific (CaC)	TT5HONZ	NOUNIPROTAC	Blocker	[3]
Potassium channel unspecific (KC)	TT1VOHK	NOUNIPROTAC	Blocker	[3]
Sodium channel unspecific (NaC)	TTRK8B9	NOUNIPROTAC	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT01235156) Efficacy and Safety of Sulcardine Sulfate Tablets in Patients With Premature Ventricular Contractions. U.S. National Institutes of Health.
• [2] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [3] Electrophysiological properties of HBI-3000: a new antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocytes. J Cardiovasc Pharmacol. 2011 Jan;57(1):79-85.
• [4] Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68.
• [5] Sidedness of carbamazepine accessibility to voltage-gated sodium channels. Mol Pharmacol. 2014 Feb;85(2):381-7.
• [6] Antiepileptic drugs and relapse after epilepsy surgery. Epileptic Disord. 2008 Sep;10(3):193-8.
• [7] Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
• [8] Synthesis and pharmacological evaluation of phenylacetamides as sodium-channel blockers. J Med Chem. 1994 Jan 21;37(2):268-74.
• [9] Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
• [10] Block of neuronal tetrodotoxin-resistant Na+ currents by stereoisomers of piperidine local anesthetics. Anesth Analg. 2000 Dec;91(6):1499-505.
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] In vitro assays for repellents and deterrents for ticks: differing effects of products when tested with attractant or arrestment stimuli. Med Vet Entomol. 2003 Dec;17(4):370-8.
• [13] Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
• [14] Effect of intracoronary nicardipine on cardiac enzymes after elective percutaneous coronary intervention. Clin Cardiol. 2009 Jun;32(6):315-20.
• [15] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [16] RT-PCR and pharmacological analysis of L-and T-type calcium channels in rat carotid body. Adv Exp Med Biol. 2009;648:105-12.
• [17] Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7.
• [18] Influence of bupropion and calcium channel antagonists on the nicotine-induced memory-related response of mice in the elevated plus maze. Pharmacol Rep. 2009 Mar-Apr;61(2):236-44.
• [19] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [20] Prenatal toxicity studies in rats and rabbits with the calcium channel blocker diproteverine. Reprod Toxicol. 1996 Jan-Feb;10(1):43-9.
• [21] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [22] Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol. 1993 Nov;22(5):687-94.
• [23] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [24] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.